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Abstract
Background—Breast cancer mortality rates in South Carolina (SC) are 40% higher among
African-American (AA) than European-American (EA) women. Proposed reasons include race-
associated variations in care and/or tumor characteristics, which may be subject to income effects.
We evaluated race-associated differences in tumor biologic phenotype and stage among low-
income participants in a government-funded screening program.
Methods—Best Chance Network (BCN) data were linked with the SC Central Cancer Registry.
Characteristics of breast cancers diagnosed in BCN participants aged 47–64 years during 1996–
2006 were abstracted. Race-specific case proportions and incidence rates based on estrogen
receptor (ER) status and histologic grade were estimated.
Results—Among 33,880 low-income women accessing BCN services, repeat breast cancer
screening utilization was poor, especially among EAs. Proportionally, stage at diagnosis did not
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differ by race (607 cancers, 53% among AAs), with about 40% advanced stage. Compared to EAs,
invasive tumors in AAs were 67% more likely (proportions) to be of poor-prognosis phenotype
(both ER-negative and high-grade); this was more a result of the 46% lesser AA incidence (rates)
of better-prognosis (ER+ lower-grade) cancer than the 32% greater incidence of poor-prognosis
disease (p-values <0.01). When compared to the general SC population, racial disparities in poor
prognostic features within the BCN population were attenuated; this was due to more frequent
adverse tumor features in EAs rather than improvements for AAs.
Conclusion—Among low-income women in SC, closing the breast cancer racial and income
mortality gaps will require improved early diagnosis, addressing causes of racial differences in
tumor biology, and improved care for cancers of poor-prognosis biology.
Keywords
Breast cancer; Health disparities; Racial disparities; Low-income population; Cancer screening;
Rates and proportions
INTRODUCTION
In South Carolina (SC), as in much of the United States, women of African ancestral origin
(African-American: AA) have a 40% higher breast cancer mortality rate than do women of
European origin (European-American: EA) [1,2]. AA women are also at greater risk of
breast cancer of more advanced stage at diagnosis, and with a biologically more aggressive
phenotype, yet AAs have a lower overall breast cancer incidence [1–7]. Behavioral,
biological, sociological, and clinical factors are proposed as contributing to the higher
incidence of advanced disease in AA women and to poor survival outcomes [8–14].
However, lower socioeconomic status (SES) and associated financial barriers to care are
also strongly associated with advanced stage and poor prognosis, thus complicating analyses
of racial variations in breast cancer incidence and outcomes [15–18].
The aim of this study was to examine race-associated disparities in two of these factors—
tumor biology and stage of presentation. To minimize the confounding effects of
socioeconomic variations between AA and EA women, we restricted our analyses to women
who participated in a financially equal-access state-wide breast cancer screening program.
We were also interested in knowing whether disparities in this cohort were exaggerated or
attenuated as compared to disparities in the general SC population which includes women of
all income levels - i.e., are differences observed at state-level similar or reduced among low-
income women with comparable financial access to breast cancer screening services.
With data from a government-funded breast cancer screening program for low-income
women, the SC Best Chance Network, and from the SC Central Cancer Registry, we used
two different but complementary epidemiologic approaches to evaluate race-associated
disparities: comparisons of breast cancer case proportions, and comparisons of population-
based age-adjusted incidence rates. Incidence rates provide a somewhat different picture
than do case proportions, as they are based upon entire populations-at-risk rather than
restricted to only those women who have been diagnosed with cancer.
METHODS
Study Cohort
The study cohort was derived from the SC Best Chance Network (BCN), an initiative
focused on low-income medically-underserved women [19]. Towards reducing income
disparities in cancer survival, the 1990 Breast and Cervical Cancer Mortality Prevention Act
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created the National Breast and Cervical Cancer Early Detection Program (BCCEDP) within
the Centers for Disease Control and Prevention (CDC). This program provides funds to
state-level programs designed to meet the CDC’s mission of providing the poor with access
to services critical for early detection of breast and cervical cancer. SC launched its program
in 1991 as the SC BCN, providing services free to low-income (less than 200% of the
federal household poverty level), medically uninsured/underinsured women. The partnership
includes about 250 private and public health care providers. The program maintains data on
women utilizing these services, including breast screening and diagnostic workup. The
program also ensures that for most women with newly diagnosed breast or cervical cancer,
Medicaid eligibility is awarded to facilitate follow-on treatment for diagnosis and treatment.
The program reaches about 10% of the potentially eligible low SES women in South
Carolina, and effectively eliminates the race-associated disparities in delays between
detection, diagnosis and treatment [20] that have been observed in other settings [21].
The study period covered January 1996, when the SC Central Cancer Registry (SCCCR)
was initiated, through December 2006. Women of race other than AA or EA were excluded
due to small numbers. Age was restricted to 47–64 years, the BCN-eligible age range
common to all years of interest. Services utilization data were obtained from the BCN
program.
The SCCCR provided clinicopathologic data on all breast cancers diagnosed in BCN
participants who met study age, year and race criteria. The SCCCR includes all cancers in
SC residents diagnosed at medical facilities in SC and 16 other states. It is certified by the
North American Association of Central Cancer Registries and by the National Program of
Cancer Registries (administered by the CDC). In the latest audit relevant to this analysis, the
SCCCR had completeness (coverage) and accuracy rates of 96.9% and 96.4% respectively,
exceeding the national standards of 95% [22]. Data provided included age and year at
diagnosis, stage, histologic type, estrogen receptor (ER) expression status, progesterone
receptor (PR) expression status, histologic grade, laterality, plus whether the case was
reported by an American College of Surgeons certified facility. Staging categories followed
the Surveillance, Epidemiology and End Results (SEER) General Summary Staging System
[23]. Her2/neu data were not available. Cases were restricted to ICD-10 codes C50.0–C50.9,
and ICDO-3 codes 8000–8983. To interpret our findings in the context of racial disparities
in the general SC population, state-level data on all female breast cancers diagnosed in SC
residents (same races, ages and years) were obtained with collaboration from the SCCCR.
To evaluate BCN breast services utilization, all screening-related visits within the same
calendar year were considered one visit. A visit included a clinical breast exam and/or
mammogram, or (rarely) diagnostic workup without screening examinations; the great
majority included a mammogram.
Statistical Methods
Descriptive statistics for age and visits were mean, median, standard deviation and range.
All other variables were categorical and summarized using frequencies and percents. Racial
differences in distributions of clinicopathologic characteristics were evaluated using t-tests,
Wilcoxon rank-sum tests, chi-square tests, and Fisher’s exact tests as appropriate.
Among invasive cancers, to account for missing histologic grade or ER status a multiple
imputation approach [24,25] was used. This produces unbiased estimates if data are missing
at random (MAR) [26,27], an assumption implying that missingness is possibly associated
with values of other observed variables, but not related to the values of the missing variables
themselves. In contrast, complete case analysis (including only those cases with complete
ER and grade data) assumes data are missing completely at random (MCAR); complete
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cases are assumed to be fully representative (i.e. they form a random sample), a restrictive
and often implausible assumption. Finally, multiple imputation yields greater efficiency
since the number of cases available for analysis is increased. We constructed ten multiply-
imputed datasets from a model containing all available data, and for each dataset estimated
case numbers and incidence rates for various combinations of ER status and grade.
Resulting estimates were averaged. Percentage imputed data did not differ by race. Given
the rigorous imputation method, plus the high concordances between lower grade and
positive ER status, and between negative ER status and high grade, any bias is minor and
unlikely to alter the overall conclusions [4,26,27].
We estimated race-specific incidence rates for each stage and, among invasive cancers,
biologic phenotype as defined by ER status and histologic grade. To calculate person-years-
at-risk (denominator), we assumed that each woman who received BCN breast services
remained eligible during the entire 1996–2006 period while her age remained within 47–64
years. Each BCN participant therefore contributed between <1.0 person-years-at-risk (e.g. if
age 64 in 1996, or age 47 in 2006) and 11.0 person-years-at-risk (e.g. if age 54 or younger in
1996), independent of the number of BCN screenings received. Data on any losses/gain of
BCN eligibility status during the study period (due to changes in income or health insurance
coverage) were not available, so we also assumed that each participant remained eligible
throughout, within the age criterion. Total person-years-at-risk was corrected for SC race-
specific all-cause female mortality for these ages and time period [28,29]. Incidence rates
were age-adjusted to the US 2000 Standard Population [30], presented as cases per 100,000
person-years-at-risk for ages 47–64, and compared using standard registry methods [31].
Race-associated differences within each population (BCN and state-level) were summarized
as AA/EA ratios.
BCN and state-level rates were not compared directly, due to methodological differences in
person-years-at-risk determination. Instead, within each population the total AA invasive
cancer rate was compared to the total EA invasive cancer incidence rate, and the proportions
contributed by each phenotypic subtype within and between populations graphically
evaluated.
All analyses other than multiple imputation were conducted using Intercooled Stata Version
9.2 statistical software (StataCorp, http://www.stata.com). Multiple imputation was
performed using the MICE package [32] in R, version 2.13.1 [33]. Subsequent analyses of
multiply-imputed data sets were performed using SAS, version 9.2. All statistical tests were
2-tailed, and p-values less than 0.05 were deemed statistically significant.
This study was approved by the Medical University of South Carolina Institutional Review
Board (IRB), the University of South Carolina IRB, the SC BCN and the SCCCR.
RESULTS
For simplicity, comparisons presented are statistically significant unless otherwise indicated,
with p-values stated only for clarity (additional p-values are in Tables).
Screening Utilization in the BCN
Overall, 19,629 AA and 14,251 EA low-income women in South Carolina participated in
the BCN breast cancer screening program, accounting for 82,338 visits (Table 1). Mean ages
at first (54 years) and last (55 years) visit did not vary significantly between races. Mean
number of BCN screening visits was 2.1 per AA and 1.9 per EA participant, with median of
1 visit in each racial group (p<0.001). Fewer than half of all women attended two or more
visits within the study period: 49% of AAs and 43% of EAs.
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Among the 48% of participants for whom screening history prior to first BCN visit was
recorded, EA women reported a significantly poorer history: 17% less likely to have
received screening within the previous 12–24 months (44% of EA women vs 53% of AAs),
and 70% more likely to have been unscreened for over 5 years (19% vs 11% respectively).
A similar pattern was observed among women diagnosed with breast cancer, although not
statistically significant.
Breast Cancer Cases in the BCN
Seventy-nine percent of the 607 breast cancers diagnosed among the BCN cohort (321 AA
cases, and 286 EA cases) were detected within the BCN program, the remaining diagnosed
prior to first using BCN services or otherwise outside the program (Table 1). Almost half of
all cancers were diagnosed at first BCN visit.
Stage at diagnosis—Stage did not differ significantly between race groups, with about
16% of cases diagnosed as carcinoma in situ, and about 41% of cases diagnosed at advanced
stage (regional or distant; Table 2). Similarly, incidence rates of in situ cancer diagnosed
within the BCN did not vary significantly by race (Table 3). AAs had a lesser incidence of
invasive cancer compared to EA women: the AA/EA incidence rate ratio (RR) was 0.79
(p<0.05), and fairly consistent across localized, regional and distant stages.
Biologic phenotype—Within the BCN, biologic parameters differed significantly by race
(Table 2, Figure 1A). Of 511 invasive cancers, those in AAs were more likely to have a less
favorable biologic phenotype, with proportionately 52% more ER negative cancers, 32%
more high-grade cancers, and 67% more cancers both ER negative and high-grade (ER−/G3:
38% in AAs vs 23% in EAs).
Age-adjusted incidence rates shed a different light on the racial disparity observed using
case proportions (Table 3, Figure 1B,C). Within the BCN, the AA significantly higher
proportion of invasive cancers with poor-prognosis phenotype was in the context of a
significantly lesser incidence rate of better-prognosis breast cancer. That is, the16 more ER
−/G3 cancers per 100,000 person-years among AAs compared to EAs (RR=1.32, not
statistically significant) was overwhelmed by the 48 fewer ER+/lower-grade cancers
(RR=0.54).
Comparisons with state-level breast cancer statistics
Among SC residents of all incomes (state-level data), advanced stage was 1.35-fold more
frequent among AA women (39% of all AA cases vs 29% of all EA cases; p<0.001). In
terms of incidence rates, in situ disease was less frequent in AAs (AA/EA RR=0.82;
p<0.001; Table 3). Similarly, the invasive cancer RR was 0.92, composite of an AA lesser
incidence of localized disease (RR=0.73) but greater incidence of advanced disease
(RR=1.21; all p-values <0.001). That is, at state-level a profound race-associated disparity in
stage was apparent, a pattern not seen in the low-income BCN cohort.
Also at the state-level, AA women had an incidence rate for ER+/lower grade cancer that
was 0.56 that of EA women (Table 3; Figure 1C), a pattern very similar to the BCN. At the
same time, at state-level, AA women had a greater incidence of poor prognosis ER−/G3
breast cancer compared to EAs (RR=1.73; p-values <0.001), greater than the difference in
the BCN (RR=1.32, p>0.05). Using population-specific proportional incidence rates (Figure
1C), EAs within the BCN had a lesser proportion of ER+ cancer (and therefore a greater
proportion of ER− disease) than did EAs at state-level. ER+ cancer was less frequent among
AAs of either population, especially in the BCN, and ER− cancer was more frequent. But
race-associated differences in ER− disease were attenuated within the BCN compared to
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those at state-level. That is, the EAs within the BCN had proportionately more ER− cancer
than at state-level, roughly intermediate between AAs at state-level and AAs in the BCN.
DISCUSSION
We evaluated racial variations in breast cancer among low-income women of South
Carolina, ages 47 to 64 years, who participated in the financially equal-access BCN program
during 1996–2006. Our work is the first to estimate race-associated variations in incidence
rates as well as case proportions for breast cancer among low-income EA and AA women by
both stage and biologic phenotype. Our study has two major findings.
First, among low-income women in the BCN program who were diagnosed with breast
cancer, no significant racial differences in advanced stages of breast cancer at presentation
were noted. This is in marked contrast to women of similar ages in the general SC
population, among whom AAs were 1.35-fold more likely than EAs to present with
advanced stage breast cancer. Our findings support the observations of others [34,35] that,
among lower SES women with equal financial access to screening services, cancer stages at
presentation are similar among EA and AA women. In interpreting this finding, several
factors should be considered.
While this lack of racial difference would appear to be good news, a closer look suggests
otherwise. The goal of screening is to decrease the likelihood of presenting with advanced
disease, and to thereby improve survival. The American Cancer Society (ACS) recommends
annual mammogram and clinical breast exam for all women age 40 years and over [2],
although other groups such as the US Preventive Services Task Force have recommended
routine screening every 1–2 years, and only for women ages 50–69 years [36]. Among
women without health insurance, disproportionately large numbers are AA, providing an
explanation for high rates of advanced stage cancers at presentation among AA women in
general (in the absence of programs like the BCN) [18,37-42] and associated higher
mortality. According to the ACS, 57% of poor US women ages 50–64 during 1998–2005
had been screened within the previous 2 years, with a similar rate in South Carolina [38].
However, only about 48% of BCN participants (53% of AAs and 44% of EAs for whom
data were available) reported any breast cancer screening within 24 months prior to first
BCN visit, within or outside the BCN program, and fewer than half of all participants
returned for even one repeat BCN screening during the study period. Moreover, among
women diagnosed with breast cancer within the BCN program, any screening within the
previous 2 years was reported by only 44% (47% of AAs, 41% of EAs).
Surprisingly, then, the lack of racial disparity in stage at diagnosis observed within the BCN
can best be interpreted as resulting from low rates of prior screening among participating EA
women (compared to the expected rate based on ACS data), rather than from much
improved screening rates among AA women. Lobb et al. [34], analyzing 1999–2005 data
from the Massachusetts Breast and Cervical Cancer Early Detection Program (a BCN
parallel) concluded that the Massachusetts program appeared to mitigate the disadvantages
of living in high-poverty neighborhoods on stage at diagnosis. This was apparently not
achieved in the SC BCN cohort, where proportions of advanced stage cancers in AA women
and in EA women were similar to the high proportions (about 40%) of advanced stage breast
cancers at presentation reported for AA women in the SC general population, most of whom
are of low SES.
The apparently low screening participation rates among the BCN cohort suggests that even
after financial barriers to mammography screening are removed, other significant barriers to
accessing screening services remain. Women of low SES may not receive adequate
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education on the importance of regular screening. Barriers such as travel, childcare and time
off work may all dissuade women from seeking screening, issues particularly salient among
the poor residing in disadvantaged minority communities, and in a predominantly rural state
such as South Carolina. Further, spatial access to health care facilities has been increasingly
recognized as influencing health services participation, and poor spatial access has been
linked to higher rates of late-stage diagnosis of breast cancer [43–44]. This underlies the
foundation of the National Patient Navigator Program, an NCI-sponsored initiative in nine
large cities in the US (although no small cities or rural areas are included, and hence any
results cannot be extrapolated to SC).
Second, with respect to breast cancer biologic phenotype, the larger difference between race
groups in the BCN was in incidence rates of better-prognosis, not poor-prognosis cancer: the
greater likelihood of a poor-prognosis phenotype among AA women was largely due to the
comparatively fewer better-prognosis ER positive cancers (Figure 1). Moreover, the
considerably greater AA incidence of all ER negative cancer and especially the poor-
prognosis ER−/G3 phenotype observed at state level (RR=1.73, p<0.01) appears attenuated
within the low-income BCN cohort (RR=1.32, p>0.05), largely due to higher relative
incidence of ER−/G3 cancer among EAs in the BCN than at state-level. This should,
perhaps, not be surprising because trends in racial differences in breast cancer ER status are
subject to contextual socioeconomic influences [45]. Various risk factors have been
proposed for high rates of ER negative breast cancers, including early menarche and age at
first pregnancy, multiparity, minimal/absent breast feeding, increased waist-to-hip ratio,
social deprivation and a poor quality diet low in fruits, vegetables, phytoestrogens,
isoflavones, lignans, fiber, folate and calcium [46]. The prevalence of these factors
putatively predisposing to ER negative cancer [47–50] is greater among lower SES women,
perhaps more similarly in each race group, thus providing a possible explanation for a
smaller racial gap in ER-negative cancers in the economically more homogeneous BCN
population than in the state as a whole.
Some limitations of our study should be noted. We did not have data on type of community
(rural versus urban) or other factors which may affect screening behavior [51,52] or cancer
risk. Adams et al., studying a similar BCN population, found AA women with positive
breast cancer screening tests were 12% less likely than EAs to complete their workup after a
suspicious finding [53]. This might tend to reduce the incidence rate among AAs within the
BCN cohort, to the extent that any breast cancer diagnosis was deferred until after age 64.
We also assumed continuous eligibility for each BCN participant, without accounting for
any possible interruption due to increased income or improved health insurance status. Data
are not available from the BCN, but interruptions in eligibility may have been more frequent
among EA participants who tend to have a somewhat higher self-reported annual household
income than do AA participants [20]. This may have contributed to the lower repeat
screening rate observed in EA participants in the BCN, compared to AAs (but not the lower
prior screening rate). The (primarily EA) women with interrupted BCN eligibility may also
have been at lower risk of ER negative breast cancer and/or at higher risk of ER positive
disease by virtue of their somewhat higher SES. This would suggest that the true AA and
EA incidence rates for the various biologic phenotypes may be more similar than we have
estimated.
While strategies effectively promoting regular breast cancer screening among all low-
income women must be developed and implemented, these alone will not be sufficient to
close the racial and income gaps in incidence of poor-prognosis cancers and associated
survival rates in SC. As reported in another study of a similar BCN population, even with
equal financial access to breast services and subsequent treatment of diagnosed cancers, AA
women with poor-prognosis breast cancer are at increased risk of mortality compared to EA
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women and this cannot be attributed to any post-detection delays in care [20]. Therefore,
closing these gaps will also require addressing causes of racial and socio-economic
differences in tumor biology, and improved detection and care for poor-prognosis disease
generally, as AA women in SC are disproportionately affected by these cancers and by low
income.
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Fig. 1. Race-associated differences in invasive breast cancer biologic phenotypes
a,b: Within the BCN, case proportions (a) and age-adjusted incidence rates (b) demonstrate
different perspectives on racial disparities. Rates are cases per 100,000 person-years-at-risk
over ages 47–64. Asterisks indicate statistical significance of race-group comparisons for
specific breast cancer phenotypic subtypes: * = p<0.05; ** = p<0.01.
c: Proportional subtype incidence rates are race-specific, proportional to the total European-
American invasive breast cancer incidence rate within each population (BCN or state-level).
Gaps in the bars for African-Americans, between ER positive and ER negative subtypes,
represent race-associated differences in total incidence within each population. Lines
indicate differences in ER positive and ER negative proportions: solid lines for race-
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associated differences within each population, long-dashed lines for differences between
African-Americans in the two populations, and short-dashed dashed lines for differences
between European-Americans in the two populations.
AA = African-American; EA = European-American; ER = estrogen receptor; G = histologic
grade;
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Table 3
Invasive breast cancer age-adjusted incidence rates among Best Chance Network (BCN) participants and
South Carolina state-level rates, for women ages 47–64 years during 1996–2006. Rates have been
standardized to the European-American total rate in the BCN and in the state-level data.
Best Chance Network State-Level
African
American (AA)
Rate (95% CI)
European
American (EA)
Rate (95% CI)
AA/EA
Rate Ratio (95% CI)
AA/EA
Rate Ratio (95% CI)
Stage (no imputation)
    In situ 34.7 (25.7, 43.8) 32.2 (22.0, 42.3) 1.08 (0.72, 1.62) 0.82 (0.75, 0.89)**
    Localized 81.4 (67.1, 95.7) 104.2 (85.4, 122.9) 0.78 (0.60, 1.01) 0.73 (0.70. 0.77)**
    Regional 72.1 (58.7, 85.4) 88.1 (70.8, 105.3) 0.82 (0.62, 1.08) 1.14 (1.07, 1.22)**
    Distant 8.9 (4.2, 13.6) 11.4 (5.1, 17.8) 0.78 (0.36, 1.69) 1.79 (1.48, 2.16)**
    Stage Unknown 5.5 (1.9, 9.2) 7.8 (2.6, 12.9) 0.72 (0.28, 1.86) 1.19 (0.96, 1.46)
    Early (In situ + Localized) 116.1 (99.2, 133.0) 136.3 (115.0, 157.6) 0.85 (0.69, 1.06) 0.76 (0.72, 0.79)**
    Advanced (Regional + Distant) 80.9 (66.8, 95.1) 99.5 (81.2, 117.9) 0.81 (0.63, 1.05) 1.21 (1.14, 1.29)**
    All Invasive Cases 167.9 (147.5, 188.3) 211.4 (184.7, 238.1) 0.79 (0.66, 0.95)* 0.92 (0.88, 0.96)**
ER/Grade in Invasive Cancers only (imputed data)
    ER+/any grade 85.6 (69.4, 101.8) 145.4 (121.8, 169.1) 0.59 (0.46, 0.76)** 0.69 (0.65, 0.72)**
    ER−/any grade 82.3 (66.2, 98.3) 66.0 (48.8, 83.2) 1.25 (0.91, 1.71) 1.61 (1.50, 1.73)**
    ER+/Grade 1 18.5 (10.5, 26.6) 27.1 (14.9, 39.2) 0.69 (0.37, 1.28) 0.48 (0.44, 0.53)**
    ER+/Grade 2 36.9 (26.3, 47.5) 76.4 (59.4, 93.4) 0.48 (0.33, 0.70)** 0.61 (0.57, 0.65)**
    ER+/Grade 3 30.2 (20.6, 39.8) 42.0 (28.8, 55.3) 0.72 (0.46, 1.13) 1.00 (0.92, 1.10)
    ER−/Grade 1 or 2 17.8 (9.4, 26.1) 17.2 (7.1, 27.2) 1.04 (0.50, 2.13) 1.27 (1.10, 1.48)*
    ER−/Grade 3 64.5 (50.9, 78.1) 48.8 (34.4, 63.3) 1.32 (0.93, 1.87) 1.73 (1.59, 1.89)**
    ER+/Grade 1 or 2 55.4 (42.7, 68.1) 103.4 (83.3, 123.5) 0.54 (0.39, 0.73)** 0.56 (0.53, 0.60)**
CI = Confidence interval;
*
=p < 0.05;
**
=p < 0.01
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